Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 106

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 106
---
 human interaction is required. We will prioritize establishing robust systems for our telemedicine services and biological sample logistics with the general health regulations of each country where we operate, with no specific regulatory framework governing these areas. Our immediate priority for biological sample logistics is to establish seamless operations coinciding with the launch of our processing hub in Mexico. This hub will streamline sample handling and logistics across the region. Following this, we will introduce telemedicine services as part of our broader commercialization strategy. These services will comply with regulatory requirements and address the healthcare needs specific to each market. However, if new regulatory frameworks emerge that apply to telemedicine services, whether for human professionals or AI Agents, the handling of biological samples, or the cross -bordertransfer of biological data, we may need to adjust our operations to adapt to these regulations. Any new regulations could be more stringent than those in place in the countries where our tests are developed and used, potentially affecting the scope or method of service delivery. Further, new regulations may mandate additional oversight regarding the professionals authorized to conduct tests, analyze results, or sign reports. Such requirements could conflict with our existing agreements with distribution partners, laboratories, and healthcare professionals. In that case, we may be forced to renegotiate existing agreements, potentially incurring additional costs and delays. If we are unable to adapt to these regulatory changes effectively, or if we face challenges in securing the necessary authorizations under new frameworks, it could materially impact our business operations, financial condition and growth prospects. We are subject to risks associated with transactions denominated in foreign currency and with currency exchange rate fluctuations, which could adversely affect our operating results. As a result of our international operations, we receive a portion of our revenues and pay a portion of our expenses in currencies other than the U.S. dollar, such as the Mexican and Argentinian pesos, in particular as substantially all of our sales are made in Argentina. In addition, many of our distribution agreements contain clauses requiring regular 27 U.S. dollar price re -adjustmentsto account for fluctuations in the exchange rate between the U.S. dollar and the local currency. As a result, we are at risk from exchange rate fluctuations between such foreign currencies and the U.S. dollar, which could adversely affect our results of operations. See “ — Adverse economic or market conditions, including inflation and the global macroeconomic environment, could negatively impact our business, financial condition and results of operations.” Additionally, the volume of our international orders may be negatively impacted by the U.S. dollar. Foreign policies and actions regarding